MediGence: Enabling Better Health Decisions

The first FDA-licensed drug for children with Menkes disease is Zycubo (copper histidinate) injection, which was approved by the U.S. Food and Drug Administration (FDA). This is a major step forward for the treatment of rare medical disorders. This landmark decision has given families affected by this excruciating and fatal genetic disorder, for which there were previously no approved treatment options, fresh hope.

The FDA claims that early Zycubo treatment greatly increases survival; children who start treatment within the first month of birth have a 78% lower risk of dying than kids who do not receive medication. This approval is a significant advancement in pediatric rare illness treatment for a disorder where the majority of children do not survive past early childhood.

What Is Menkes Disease?

Menkes disease is a rare hereditary neurological condition caused by mutations in the ATP7A gene, which is essential for the body's transport of copper. The growth of the brain, the production of connective tissue, and the healthy operation of the neurological and circulatory systems all depend on copper.

Despite adequate dietary consumption, children with Menkes disease have widespread copper shortage because their bodies are unable to properly absorb and distribute copper. Many organ systems are impacted as a result.

Because the condition is X-linked recessive, it mostly affects boys and is inherited from carrier moms. Globally, it affects between 1 in 100,000 and 250,000 live births; however, more recent genetic research indicates that it could affect up to 1 in 8,664 male births.

Symptoms and Disease Progression

About 90% of patients have classic Menkes disease, which typically presents in early infancy. Common symptoms include:

Seizures
Failure to thrive and poor weight gain
Developmental delays and intellectual disability
Low muscle tone (hypotonia)
Weak bones and skeletal abnormalities
Abnormal blood vessels and connective tissue
Distinctive hair that is thin, light-colored, coarse, and wiry

Without treatment, disease progression is rapid and severe. Historically, most children with classical Menkes disease do not survive beyond three years of age, making early diagnosis and intervention critical.

What Is Zycubo and How Does It Work?

Zycubo (copper histidinate) is a copper replacement therapy administered via subcutaneous (under-the-skin) injection. Unlike dietary copper, which cannot be properly absorbed due to a genetic defect, Zycubo delivers copper in a bioavailable form that bypasses the faulty intestinal absorption pathway.

By providing copper directly into the body, Zycubo helps restore copper-dependent biological processes essential for neurological development, growth, and overall survival.

Zycubo is administered daily or twice daily, depending on the childâ€™s age, and caregivers can be trained to give injections at home.

Clinical Trial Evidence Behind FDA Approval

The FDA's approval of Zycubo was based on data from two open-label, single-arm clinical trials involving pediatric patients treated for up to three years. Because Menkes disease is ultra-rare, treated patients were compared with external, contemporaneous, untreated control groups.

The analysis included:

66 treated patients
17 untreated control patients, most from the United States

Key Trial Findings

Children who began treatment within four weeks of birth had a 78% lower risk of death
Nearly 50% of early-treated children survived beyond six years
Some patients lived more than 12 years
No untreated patients survived beyond six years
Children who started treatment later than four weeks still experienced a significant survival benefit

FDA experts highlighted the innovative trial design, which successfully addressed the challenges of studying an ultra-rare pediatric disease while demonstrating a clear survival advantage.

Safety and Side Effects

Although Zycubo was usually well tolerated, there are some dangers associated with any medication. Among the most often mentioned adverse effects were:

Infections (viral, bacterial, and fungal)
Respiratory complications
Seizures
Vomiting and fever
Anaemia (low red blood cell count)
Elevated liver enzymes
Injection site reactions
Low blood pressure and rapid heart rate

Patients using Zycubo need to be regularly watched for symptoms of copper toxicity since copper can build up in the body.

Monitoring and Treatment Considerations

Before starting Zycubo, healthcare providers assess copper levels, blood counts, and liver and kidney function. During treatment, regular monitoring is required:

Every 6 weeks for the first 6 months
Every 3 months for the next 18 months
Every 6 months thereafter
If abnormalities occur, dosing may be reduced, paused, or discontinued with increased monitoring.

It is important to note that Zycubo is not approved for occipital horn syndrome, a related but distinct copper transport disorder.

The Significance of This Approval

The FDA granted Zycubo Priority Review, Fast Track, Breakthrough Therapy, and Orphan Drug Designations, underscoring the urgent unmet medical need it addresses. With its approval for Sentynl Therapeutics, Zycubo represents a breakthrough in the management of Menkes disease.

In addition to prolonging survival, Zycubo gives families dealing with this uncommon condition new hope for better results through prompt diagnosis and treatment.

How MediGence Supports Families Affected by Rare Diseases

Managing a rare and life-threatening condition like Menkes disease requires timely diagnosis, access to specialised expertise, and coordinated care. MediGence helps patients and families navigate these challenges by connecting them with leading pediatric neurologists, genetic specialists, and rare-disease treatment centres worldwide.

MediGence guarantees that families receive accurate information and access to cutting-edge therapies through individualised case evaluation, professional medical opinions, and support with treatment planning at internationally approved facilities. Our team is dedicated to helping families achieve the best outcomes for children with uncommon and complex diseases, from early consultation through ongoing care coordination.